Market Place
Sourcing Support
NLS Secures Patent In Japan For Mazindol ER For Heroin Dependence
21 Oct 2024 //
ACCESSWIRE
NLS Pharma: Mazindol Neuroprotection In Narcolepsy Rat Model
28 May 2024 //
ACCESSWIRE
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program for Mazindol ER
03 Jul 2023 //
ACCESSWIRE
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450
14 Jun 2023 //
ACCESSWIRE
NLS Receives Green Light from the USFDA to Proceed with Ph3 Program (AMAZE)
02 May 2023 //
BUSINESSWIRE
NLS Announces Label Extension Study Six-Month Data for Quilience Mazindol ER
27 Mar 2023 //
ACCESSWIRE
NLS Announces Completion of Extension Study with Quilience(R) (Mazindol ER)
30 Jan 2023 //
ACCESSWIRE
NLS Pharma Announces Notice of Allowance for U.S. Patent Covering Mazindol
01 Dec 2022 //
ACCESSWIRE
NLS Pharma Provides Open Label Extension Study Update for Quilience(R)
07 Nov 2022 //
ACCESSWIRE
U.S. FDA Grants Orphan Drug Designation (ODD) for Quilience(R) (Mazindol ER)
02 Nov 2022 //
ACCESSWIRE
Novartis` Sanorex at center of New Jersey pharma chief`s guilty plea
16 Aug 2022 //
FIERCEPHARMA
Swiss biotech NLS touts positive ADHD data, plots late-stage tests
31 May 2017 //
FIERCE BIOTECH
Mazindol Granted Orphan Drug Designation in the US & Europe for Narcolepsy
11 Jul 2016 //
PR NEWSWIRE
Dr Reddys` Generic Palonosetron Hydrochloride approved in US
20 Apr 2016 //
FDA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.